Alnylam Defends Heart Disease Drugs Following AstraZeneca's Wainua Trial Failure
Source Summary
AstraZeneca's Wainua heart disease trial has failed, creating pressure on Alnylam to defend its own medicines in the same therapeutic area. Alnylam is mounting a defense of its heart disease drug candidates in response to the trial setback.
Why it matters
The failure of a competitor's heart disease trial raises questions about the viability of similar drug approaches, directly affecting investor confidence in Alnylam's pipeline in this therapeutic area.
